Initial Guidance Established for Medicare Drug Price Negotiation Program for Price Applicability Year 2026

For the first time, Medicare will have the ability to negotiate lower prescription drug prices because of the Inflation Reduction Act, a law that lowers healthcare and prescription drug costs.

HHS Creates New Office of Family Violence Prevention and Services

The U.S. Department of Health and Human Services has announced a new Office of Family Violence Prevention and Services under the Administration for Children and Families Act.

Grants Provided for Certified Behavioral Health Clinics

Two funding opportunities for Certified Community Behavioral Health Clinic expansion, totaling $123.6 million, were made available by the U.S. Department of Health and Human Services.

HHS Issues Amendment to PREP Act for Medical Countermeasures Against COVID-19

The U.S. Department of Health and Human Services (HHS) has issued an amendment to the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19.

Experimental mRNA Vaccine Plus Keytruda Delays Melanoma Recurrence

A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.

FDA Retires Monovalent COVID-19 Vaccines

The U.S. Food and Drug Administration has amended the emergency use authorizations of the. Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.

Study Finds Experimental Alzheimer’s Drug Slows Cognitive Decline

A large clinical trial of Eli Lilly’s experimental Alzheimer’s medication, donanemab found the drug slowed declines in patients’ ability to think clearly and perform daily tasks by more than a third.

Pfizer’s LITFULO for Severe Alopecia Areata Approved by FDA

The U.S. Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.

First Subcutaneous Injectable Approved to Treat Generalized Myasthenia Gravis

The subcutaneous formulation of argenx’s Vyvgart has been approved by the U.S. Food and Drug Administration to treat generalized myasthenia gravis.

FDA Approves Roche’s Columvi to Treat Diffuse Large B-Cell Lymphoma in Adults

The U.S. Food and Drug Administration has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab.